(140 days)
No
The description focuses on real-time data acquisition, analysis, and 3D mapping using sensor and location technology, without mentioning AI or ML.
No.
The CARTO® 3 System is a diagnostic and navigation tool used in cardiac electrophysiological procedures to map the heart's electrical activity and catheter location. It provides information to guide procedures but does not directly treat a condition. Instead, it supports catheter-based EP procedures which are therapeutic.
Yes
The device provides information about the electrical activity of the heart and catheter location, and creates 3D anatomical and electroanatomical maps based on acquired data points and electrograms. This information is used for diagnosis and planning of catheter-based cardiac electrophysiological procedures.
No
The device description explicitly states it is a "catheterbased atrial and ventricular mapping system" that acquires data using a "specialized mapping catheter and reference device." This indicates the system includes hardware components beyond just software.
Based on the provided information, the CARTO® 3 System is not an In Vitro Diagnostic (IVD) device.
Here's why:
- IVD Definition: In Vitro Diagnostics are devices intended for use in the examination of specimens derived from the human body (such as blood, urine, or tissue) to provide information for the diagnosis, monitoring, or treatment of a disease or condition.
- CARTO® 3 System Function: The CARTO® 3 System is described as a system for catheter-based cardiac electrophysiological procedures. It acquires and analyzes electrical activity and catheter location within the human heart in real-time. It does not analyze specimens derived from the body.
- Intended Use: The intended use clearly states it's for "catheter-based cardiac electrophysiological (EP) procedures" and provides information about "electrical activity of the heart and about catheter location during the procedure." This is an in vivo (within the living body) application, not in vitro (in glass or outside the living body).
Therefore, the CARTO® 3 System falls under the category of a medical device used for in vivo procedures, not an In Vitro Diagnostic device.
N/A
Intended Use / Indications for Use
The intended use of the CARTO® 3 System is catheter-based cardiac electrophysiological (EP) procedures. The CARTO® 3 System provides information about the electrical activity of the heart and about catheter location during the procedure. The system can be used on patients who are eligible for a conventional electrophysiological procedure. The system has no special contraindications.
Product codes (comma separated list FDA assigned to the subject device)
DQK
Device Description
The CARTO®3 EP Navigation 3 System, Version 3.2 and Accessories is a catheterbased atrial and ventricular mapping system designed to acquire and analyze data points, and use this information to display 3D anatomical and electroanatomical maps of the human heart in real-time. The location information needed to create the cardiac maps and the local electrograms are acquired using a specialized mapping catheter and reference device. The system allows real-time display of electrograms and cardiac maps based on the received intracardiac signals from the catheters in a number of different formats. The acquired patient signals, including body surface ECG and intracardiac electrograms (IECG) may also be displayed on the display screen. The CARTO® 3 System V3.2 uses two distinct types of location technology magnetic sensor technology and Advanced Catheter Location (ACL) technology.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
human heart
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
The CARTO® 3 EP Navigation System, Version 3.2 underwent extensive Bench and Animal Testing to verify the modified features and to demonstrate with regression testing that the new features did not negatively affect existing features. The CARTO® 3 EP Navigation System, Version 3.2 passed all tests in accordance with appropriate test criteria and standards, and the CARTO® 3 EP Navigation System, Version 3.2 and Accessories did not raise new questions of safety or effectiveness.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s): If the device was cleared using the 510(k) pathway, identify the Predicate Device(s) K/DEN number used to claim substantial equivalence and list them here in a comma separated list exactly as they appear in the text. List the primary predicate first in the list.
Reference Device(s): Identify the Reference Device(s) K/DEN number and list them here in a comma separated list exactly as they appear in the text.
Predetermined Change Control Plan (PCCP) - All Relevant Information for the subject device only (e.g. presence / absence, what scope was granted / cleared under the PCCP, any restrictions, etc).
Not Found
§ 870.1425 Programmable diagnostic computer.
(a)
Identification. A programmable diagnostic computer is a device that can be programmed to compute various physiologic or blood flow parameters based on the output from one or more electrodes, transducers, or measuring devices; this device includes any associated commercially supplied programs.(b)
Classification. Class II (performance standards).
0
JAN 2 4 2014
14 510(K) SUMMARY
-" " ::
i
14.1 General Information
| Applicant: | Biosense Webster, Inc.
3333 Diamond Canyon Road
Diamond Bar, CA 91765 USA
Phone: 909-839-8597
Fax: 909-839-8804 |
|--------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Date: | September 3, 2013 |
| Contact Person: | Wayne R. Hohman
Project Manager Regulatory Affairs |
| Authored By: | Moshe Hochmitz
Quality and Regulatory Manager
Biosense Webster (ISRAEL), Ltd. |
| Trade/Proprietary Device Name: | CARTO® 3 EP Navigation System, Version 3.2 and
Accessories |
| Manufacturing Part Number: | FG-5400-00 |
| Common Device Name: | Cardiac mapping system |
| Classification Name: | Programmable diagnostic computer
Class II, 21 CFR 870.1425, Product Code DQK |
| Predicate Device: | CARTO® 3 EP Navigation System, Version 3.0 and
Accessories
510(k) K120550, May 7, 2012 |
| | Reference Device:
CARTO® 3 XP EP Navigation, System Version 1.0
510(k) K093566, June 18, 2010 |
| Manufacturing Facilities: | Biosense Webster (Israel), Ltd.
a Johnson & Johnson Company
4 Hatnufa Street, POB 275
Yokneam 20692
ISRAEL
Biosense Webster, Inc.
a Johnson & Johnson Company
3333 Diamond Canyon Road
Diamond Bar, California 91765 USA |
Biosense Webster, Inc.
CARTO® 3 EP Navigation System, V3.2
Traditional 510(k)
Page 5 of 268
1
14.2 Substantial Equivalence
ﺪ ﺍﻟﻤﺪﻳﻨﺔ ﺍﻟﻤﺘﺤﺪﺓ ﺍﻟﻤﺘﺤﺪﺓ ﺍﻟﻤﺘﺤﺪﺓ ﺍﻟﻤﺘﺤﺪﺓ ﺍﻟﻤﺘﺤﺪﺓ ﺍﻟﻤﺘﺤﺪﺓ ﺍﻟﻤﺘﺤﺪﺓ ﺍﻟﻤﺘﺤﺪﺓ ﺍﻟﻤﺘﺤﺪﺓ ﺍﻟﻤﺘﺤﺪﺓ ﺍﻟﻤﺘﺤﺪﺓ ﺍﻟﻤﺘﺤﺪﺓ ﺍﻟﻤﺘﺤﺪﺓ ﺍﻟﻤﺘﺤﺪﺓ ﺍﻟﻤﺘﺤﺪﺓ ﺍﻟﻤﺘﺤﺪﺓ ﺍﻟﻤﺘﺤﺪﺓ ﺍﻟﻤﺘﺤﺪﺓ ﺍﻟﻤﺘﺤﺪﺓ ﺍﻟﻤﺘﺤﺪﺓ ﺍﻟﻤ
The CARTO® 3 EP Navigation System, Version 3.2 and Accessories are substantially equivalent to the legally marketed CARTO® 3 EP Navigation System, Version 3.0 and Accessories and the CARTO® XP EP Navigation System. Version 10 as shown in Table 7:
| Table 7
| Predicate Devices for CARTO® 3 EP Navigation System, Version 3.2 | ||
|---|---|---|
| Device Name | 510(k) | |
| Number | Equivalence Criteria | |
| CARTO® 3 EP Navigation System, | ||
| Version 3.0 and Accessories | K120550 | Legacy Functionality |
| CARTO XP EP Navigation | ||
| System, Version 10 | K093566 | Pace Mapping Software (PaSo™) |
| Module |
14.3 Description of Device
The CARTO®3 EP Navigation 3 System, Version 3.2 and Accessories is a catheterbased atrial and ventricular mapping system designed to acquire and analyze data points, and use this information to display 3D anatomical and electroanatomical maps of the human heart in real-time. The location information needed to create the cardiac maps and the local electrograms are acquired using a specialized mapping catheter and reference device. The system allows real-time display of electrograms and cardiac maps based on the received intracardiac signals from the catheters in a number of different formats. The acquired patient signals, including body surface ECG and intracardiac electrograms (IECG) may also be displayed on the display screen. The CARTO® 3 System V3.2 uses two distinct types of location technology magnetic sensor technology and Advanced Catheter Location (ACL) technology.
14.4 Indications for Use
The intended use of the CARTO® 3 System is catheter-based cardiac electrophysiological (EP) procedures. The CARTO® 3 System provides information about the electrical activity of the heart and about catheter location during the procedure. The system can be used on patients who are eligible for a conventional electrophysiological procedure. The system has no special contraindications.
14.4a Technological Characteristics
The Proposed CARTO® 3 Electrophysiology Navigation System. Version 3.2, has the same technological characteristics (i. e., design, material, chemical composition, energy source) as the predicate CARTO® 3 Electrophysiology Navigation System, Version 3.0. A summary of the technological characteristics of the new device compared to the predicate device is as follows:
Biosense Webster, Inc. CARTO® 3 EP Navigation System, V3.2
Biosense Webster, Inc. CARTO® 3 EP Navigation System, V3.2 Traditional 510(k) Page 88 of 2538
Traditional 510(k) Page 6 of 268
2
- . The hardware platform of the new Version 3.2 is identical to the predicate Version 3.0.
- . The differences between Versions 3.2 and 3.0 involve only software as follows:
- The main change in this submission is to activate an installed but previously o blocked SMARTTOUCHTM Module.
- o The software of three other features of this system is enhanced (i. e., updated) in this submission: 1) Advanced FAM - Visual improvement of the V2 FAM Feature, 2) Remote Magnetic Technology (RMT) Improvements, and 3) Video Export to Recording System.
- o Finally, Biosense Webster is updating FDA on a feature that was incorporated via 510(k) Letter to File since the last submission: Improved Pace Mapping Software (PaSoTM) Module. The PaSoTM Module was originally cleared via in an earlier version of this device and this device is included in this Application as a Reference Device for the PaSo™ Module feature: CARTO® XP EP Navigation System, Version 10 (510(k) K093566, cleared June 18, 2010).
14.5 Summary of Non-Clinical Performance Testing
The CARTO® 3 EP Navigation System, Version 3.2 underwent extensive Bench and Animal Testing to verify the modified features and to demonstrate with regression testing that the new features did not negatively affect existing features. The CARTO® 3 EP Navigation System, Version 3.2 passed all tests in accordance with appropriate test criteria and standards, and the CARTO® 3 EP Navigation System, Version 3.2 and Accessories did not raise new questions of safety or effectiveness.
14.6 Conclusions
. ...
Extensive Non-Clinical (Bench) Testing, Animal Testing, and an IDE Clinical Investigation all demonstrated that the CARTO® 3 EP Navigation System, Version 3.2 and Accessories as used with the activated SMARTOUCH® Module are as safe, as effective, and performs as well as or better than the Predicate Device and the Reference Device. This testing program supports the determination of substantial equivalence of the CARTO® 3 EP Navigation System, Version 3.2 and Accessories to existing predicate devices.
Biosense Webster, Inc. CARTO® 3 EP Navigation System, V3.2
Biosense Webster, Inc. CARTO® 3 EP Navigation System, V3.2 Traditional 510(k) Page 89 of 2538
Traditional 510(k) Page 7 of 268
3
DEPARTMENT OF HEALTH & HUMAN SERVICES
Image /page/3/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo features a stylized caduceus, a symbol often associated with medicine and healthcare. The words "DEPARTMENT OF HEALTH & HUMAN SERVICES-USA" are arranged in a circular pattern around the caduceus.
Public Health Service
Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-0002
January 24, 2014
Biosense Webster, Inc. Wayne Hohman 3333 Diamond Canyon Rd Diamond Bar, CA 91765 US
K132782 Re:
Trade/Device Name: CARTO 3 EP Navigation System, version 3.2 Regulation Number: 21 CFR 870.1425 Regulation Name: Programmable Diagnostic Computer Regulatory Class: Class II Product Code: DQK Dated: November 5, 2013 Received: November 6, 2013
Dear Mr. Hohman:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
4
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Division of Small Manufacturers, International and Consumer Assistance at its tollfree number (800) 638-2041 or (301) 796-7100 or at its Internet address
http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to
http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.
You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638 2041 or (301) 796-7100 or at its Internet address
http://www.fda.gov/MedicalDevices/Resourcesfor You/Industry/default.htm.
Sincerely yours.
Owen P. Faris -S
for
Bram D. Zuckerman, M.D. Director Division of Cardiovascular Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
5
510(k) No (if known):
Device Name: CARTO® 3 EP Navigation System, Version 3.2
Indications for Use:
The intended use of the CARTO® 3 System is catheter-based cardiac electrophysiological (EP) procedures. The CARTO® 3 System provides information about the electrical activity of the heart and about catheter location during the procedure. The system can be used on patients who are eligible for a conventional electrophysiological procedure. The system has no special contraindications.
Prescription Use ___ V (Part 21 CFR 801 Subpart D)
AND/OR
Over-The-Counter Use (21 CFR 801 Subpart C)
(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH, Office of Device Evaluation (ODE)
Digitally signed by.
Owen P. Faris -S
Date: 2014.01.24
16:20:52 -05'00'
Biosense Webster, Inc. CARTO® 3 EP Navigation System, V3.2
Biosense Webster, Inc. CARTO® 3 EP Navigation System, V3.2 Traditional 510(k) Page 42 of 2538
Traditional 510(k) Page 9 of 268